#USA #New York #Ulcerative Colitis #Evinature #CurQD

Evinature's CurQD Selected for Department of Defense Funded Clinical Trial

Evinature, known for its pioneering contributions to nutraceutical formulations, has recently made headlines with the announcement that its flagship product, CurQD, has been selected for a clinical trial funded by the U.S. Department of Defense (DoD). This groundbreaking study aims to explore a novel combination approach for treating ulcerative colitis, a debilitating condition affecting many in the military community.

The trial, which is being conducted at Mount Sinai Hospital in New York in collaboration with the University of Chicago Medicine and Sheba Medical Center in Israel, has an initial planning grant of $800,000. It could potentially receive up to $11 million in funding to facilitate the completion of the research.

Understanding Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory bowel disease that primarily affects the large intestine, leading to severe gastrointestinal discomfort and significantly impacting patients' quality of life. In the United States alone, about 1.25 million people are affected, with military personnel at a higher risk due to unique environmental exposures associated with their service.

The Significance of the DoD's Involvement

The decision for the DoD to fund this research underscores the severe impact ulcerative colitis has on a significant number of military health-care beneficiaries; estimates suggest more than 35,000 military individuals are currently managing this condition. Notably, the incidence of ulcerative colitis among active duty members is approximately 50% higher than in the general population. This has prompted the research community to investigate potential causal factors and innovative treatment methodologies, especially considering the unique experiences of military personnel.

A Novel Combination Approach with CurQD

The trial settings will employ Evinature's CurQD, a plant-based formulation comprising curcumin and QingDai, alongside vedolizumab, an established biologic commonly prescribed for managing ulcerative colitis and Crohn's disease. This combination aims to utilize the distinct mechanisms of both treatments to enhance efficacy.

As explained by Dr. Ryan Ungaro, the principal investigator from Mount Sinai, the motivation behind investigating this unique combination lies in addressing patient interests in non-pharmacological supportive treatments that can complement conventional care. Dr. Ungaro noted, “We believe that patients are quite interested in the idea of using a non-pharmacological complementary approach to support the effectiveness of their care.”

Evidence-Based Formulation of CurQD

CurQD stands out due to its carefully designed formulation, which has undergone rigorous testing. In a randomized, double-blind, placebo-controlled trial, CurQD showed efficacy among patients dealing with active ulcerative colitis. The formulation leverages curcumin's anti-inflammatory properties while incorporating QingDai, aligning with evolving guidelines in the management of inflammatory bowel diseases.

This emphasizes the growing recognition of nutraceuticals in providing supportive care for chronic bowel issues, as outlined by the European Crohn's and Colitis Organisation's recent consensus guidelines.

International Collaboration to Advance Research

The clinical trial's international collaboration between Mount Sinai, the University of Chicago, and Sheba Medical Center enhances the potential for groundbreaking insights into ulcerative colitis treatment. Sheba Medical Center's Dr. Shomron Ben-Horin emphasized that this study’s unique focus on a combination of a pharmaceutical and a plant-based nutraceutical could lead to superior outcomes for patients.

Evinature's commitment to advancing clinically validated natural compounds in the realm of digestive health is evident. Their dedication to rigorous scientific research and quality control bridges the gap between traditional medicine and the growing interest in integrative health approaches.

Conclusion: The Future of Ulcerative Colitis Treatment

As the study progresses, the implications of CurQD may extend beyond ulcerative colitis, potentially influencing a range of inflammatory bowel diseases and setting new standards for how such conditions can be managed. Given the significant economic burden associated with inflammatory bowel diseases, which ranges between $14.6 to $31.6 billion annually in the U.S., the urgency for innovative solutions like the combination efficacy of CurQD and vedolizumab cannot be overstated. As this landmark trial unfolds, the anticipation surrounding its results reflects both hope and a commitment to improving lives affected by ulcerative colitis and related disorders.